CGM for Healthy People: Useful N=1 Toy, or Marketing in a Sticker?

A continuous glucose monitor (CGM) is a small filament sensor that sits in the fat tissue just under the skin of your upper arm. First surprise: it does not measure blood glucose. It measures glucose in the interstitial fluid (the watery space between cells) and estimates your blood value from there. Interstitial glucose lags capillary blood by roughly 5 to 15 minutes, longer during sharp rises or drops. That is why a CGM curve can look quite different from a finger-prick reading taken in the same second.

Accuracy is reported as MARD, short for Mean Absolute Relative Difference. A 2024 head-to-head by Hanson and colleagues in 55 adults with diabetes (33 T1D + 23 T2D) reported point-accuracy MARD of 8.9 percent for FreeStyle Libre 3 and 13.6 percent for Dexcom G7 against laboratory reference. Accuracy in healthy normoglycemic ranges may differ. Manufacturer registration trials report different numbers (often closer to 8 to 9 percent for both), because population, reference method, and glucose range all matter a lot.

The practical takeaway: a value of 95 mg/dL could plausibly sit anywhere between 86 and 104 mg/dL in real blood. Two sensors on the same arm will disagree, sometimes by 15 mg/dL. That is the technology working as designed, not a defect.

Devices you will see in DACH: Abbott FreeStyle Libre 3, Dexcom G7, and Dexcom ONE+ (all CE-marked and mostly prescribed for diabetes). On the consumer side: Abbott Lingo (UK + US launch 2024) and Dexcom Stelo (US 2024, European rollout still ongoing). Platforms like Hello Inside (an Austrian start-up from Vienna) pair a third-party sensor with a coaching app.

Most healthy adults sit around 99 mg/dL on average, with brief postprandial peaks to 130 to 140 mg/dL. That number comes from Shah and colleagues 2019 in the Journal of Clinical Endocrinology and Metabolism. They put CGMs on 153 nondiabetic adults across multiple US sites and recorded continuous glucose for several days. Here is what they found:

• Mean 24-hour glucose: 99 ± 7 mg/dL.
• Time spent between 70 and 140 mg/dL: a median of 96 percent (IQR 93 to 98).
• Time above 180 mg/dL: effectively zero.

People aged 60 and over spent measurably more time above 140 mg/dL than younger adults. But even healthy young adults occasionally crossed 140, usually only briefly after meals.

A bigger 2025 community cohort (Spartano, same journal) backed this up. It followed a much larger group of adults without diabetes (n=560 normoglycemic) and saw the same picture. Mean time-in-range (70 to 180 mg/dL) was 97.8 percent (SD 4.9), and median time above 180 mg/dL was negligible. The real distribution is narrower than commercial CGM apps tend to suggest.

Time above 180 mg/dL is uncommon, but not zero. Roughly 20 percent of normoglycemic adults still spent more than 2 percent of their time above 180 mg/dL. And median time in the tight range, 70 to 140 mg/dL, was about 87 percent.

The paper consumers cite most is Hall and colleagues 2018 in PLOS Biology, which coined the term "glucotypes". The Stanford team ran CGM and standardized meal tests on 57 adults. Postprandial responses to identical meals varied widely between people. Three distinct patterns emerged (low, moderate, severe variability), even in adults classified as normoglycemic by HbA1c. This is where the popular claim that everyone responds differently to food comes from. The claim is true, and the data are interesting. They also come from a 57-person observational study with no longevity or cardiovascular outcomes attached.

The ATTD international consensus (Battelino, Diabetes Care 2019) defines clinical CGM targets, but explicitly for people with diabetes. There is no consensus on what time-in-range means or matters for non-diabetic adults. The ADA Standards of Care 2025 (Section 7) limits its OTC-CGM recommendation to people with prediabetes or with diabetes not on insulin. It does not endorse CGM as a routine longevity or wellness tool in healthy adults. The 2026 update notes that OTC biosensors are also bought by people without diabetes who want to watch their glycemic responses to lifestyle, but stops short of a clinical recommendation for healthy users.

A CGM can teach you a few real things about your own body. Meal-by-meal differences in your postprandial curves are the obvious one: white bread alone versus the same bread eaten after a walk, or alongside protein and fat, will produce different rises. This is your data, not a population average. You can also watch the effect of poor sleep on next-morning fasting glucose and tolerance. The Oganesova 2024 review flagged that as one of the more reproducible findings from consumer CGM use. And you can see what alcohol, illness, stress, and intense exercise do to your curve.

There is a much longer list of things a CGM cannot tell you. It cannot diagnose prediabetes or diabetes: those need fasting glucose, OGTT (oral glucose tolerance test), and HbA1c, not CGM peaks. It cannot tell you that a spike to 150 mg/dL is bad. It cannot tell you whether your spike pattern predicts heart disease or mortality 20 years from now, because no randomized trial in healthy adults has ever tested that question. And it cannot tell you to go low-carb, keto, carnivore, or fasting. Those are clinical decisions that belong with a Hausarzt or a registered dietitian.

The most honest framing is this: a CGM is a structured n=1 experiment. Treat it as a curiosity tool to spot patterns and bring anomalies to a physician, and it can be useful. Treat it as a daily report card, and it more often produces anxiety, food avoidance, and overcorrection that is itself unhealthy.

The CGM-for-wellness market is a textbook case of a strong biomarker chasing a much weaker outcome story. Abbott (Lingo), Dexcom (Stelo), Levels Health (US-only, not available in DACH), NutriSense (US), Zoe (UK; uses CGM as one input in its nutrition program), Hello Inside (Austria), Veri (Finland), Glucura and Una Health (Germany) all build on a real signal: postprandial glucose varies between people and foods. Then they stretch it into claims about metabolic health and longevity that the evidence does not yet support.

The FDA cleared the first two OTC consumer CGMs in 2024: Dexcom Stelo in March and Abbott Lingo later that year. Both are sold without a prescription to adults 18 and over who are not on insulin. That is a regulatory permission slip, not an outcome study. It means the devices are safe enough for over-the-counter sale, not that wearing one improves health in healthy people.

A 2024 narrative review in Diabetic Medicine (Oganesova et al.) looked specifically at non-diabetic CGM use and reached a cautious verdict. The evidence for utility is limited and inconsistent. Commercial claims risk being misleading. Side effects like over-restriction and anxiety deserve attention, and the authors call for stricter regulation of consumer marketing. A 2021 review in BMJ Open Diabetes Research and Care (Martinez et al.) lands in the same place: glucose variability tracks with cardiovascular outcomes in type 2 diabetes, but extrapolating that to healthy adults is not warranted.

The downsides are not zero. The anchoring effect is real. People see a 145 mg/dL spike after porridge, panic, switch to bacon and eggs, and never re-examine the assumption. The orthorexia risk is real too. Case reports link CGM use to disordered eating in already-anxious users. And the cost adds up. A healthy DACH self-pay user spends roughly EUR 50 to 150 per 14-day sensor at an Apotheke. Wear one continuously and that is about EUR 700 to 1500 per year. None of it is reimbursed by GKV or private insurance without a coded diabetes diagnosis under ICD-10 E10 or E11.

Honest summary: CGM in healthy people is an interesting biomarker, not a validated longevity intervention. Treat it like a sauna habit you are testing. Try it, see if it changes anything you actually care about, then decide whether EUR 1000 per year buys more than a single private blood panel with HbA1c, fasting insulin, and OGTT.

The DACH CGM market in mid-2026 is a moving target. Check current availability at purchase time. Here is the neutral overview.

Abbott FreeStyle Libre 3 is the dominant prescription CGM in Germany and Austria. It sits on the Hilfsmittelverzeichnis (HMV) and is reimbursed by statutory health insurance only for people with a coded diabetes diagnosis under intensive insulin therapy or a comparable indication. Without that diagnosis, you can buy sensors privately through an Apotheke (as a Selbstzahler) at roughly EUR 50 to 75 per 14-day sensor. In Switzerland, CGM is covered through the Grundversicherung under KLV/MiGeL only for diagnosed diabetes meeting specific clinical criteria. Non-diabetic wellness use is not covered.

Abbott Lingo is the consumer biowearable, launched OTC in the United Kingdom and United States in 2024, and officially only available in those two markets as of May 2026. There is no official DACH (or wider EU) rollout. The older patchy-DACH-availability framing is generous. Anyone in DACH using Lingo is doing so via cross-border parcel or US/UK reshipper, with no CE-MDR pathway for direct consumer sale in DE/AT/CH.

Dexcom G7 is prescription-only in DACH for diabetes management. Dexcom Stelo, the US OTC product launched in 2024, has not yet seen a full DACH consumer launch as of mid-2026. Check the manufacturer's regional pages.

Hello Inside is a Vienna-based start-up offering a CGM-plus-coaching subscription marketed primarily to women interested in metabolic health. The sensor is a third-party Abbott device. Hello Inside is a coaching layer on top. Whether the subscription fee on top of the sensor is worth it depends on how much app guidance you value. We mention it neutrally, not as a recommendation.

A recurring confusion: DiGA-approved digital health apps in Germany (Una Health, Glucura) are reimbursed for diagnosed type-2 diabetes, not for healthy users. Do not assume insurance coverage transfers to wellness use.

For a healthy adult in DACH 2026, the realistic Selbstzahler path looks like this: buy two Libre 3 sensors at an Apotheke (about EUR 100 to 150 for one month), use the manufacturer's free app, and optionally layer a coaching service on top. No reimbursement applies.

If your goal is an evidence-based metabolic check-in, the established biomarkers are unglamorous, cheap, and well-validated. Fasting glucose plus HbA1c gives you a calibrated read on average glycemia over 8 to 12 weeks. Fasting insulin and the derived HOMA-IR score is the best non-invasive proxy for insulin resistance available to a Hausarzt. A 75 g OGTT with glucose and insulin measured at 0, 60, and 120 minutes is the gold standard for catching impaired glucose tolerance and early hyperinsulinemia before HbA1c moves.

For cardiovascular and longevity-adjacent biomarkers, the validated set is: ApoB or LDL particle number, Lp(a) at least once in a lifetime, triglycerides, hs-CRP, and HDL-C. Combined with blood pressure, waist circumference, and resting heart rate, these have decades of randomized-trial evidence behind them. CGM-derived glucose variability has none of that evidence in healthy adults.

Pragmatic comparison: in DACH 2026, a private Selbstzahler blood panel covering HbA1c, fasting glucose, fasting insulin, a lipid panel with ApoB, hs-CRP, and basic thyroid markers costs EUR 150 to 350 once per year. One year of CGM sensors as a self-pay healthy user costs EUR 700 to 1500. The blood panel has decades of outcome data behind it. The CGM has the Stanford glucotypes paper and an n=153 healthy-cohort baseline. Both can be useful. Only one is validated.

The sensible way to think about CGM for a curious longevity-minded adult: a structured two-week experiment, once, to see what your own meals and habits do to your curve, knowing the result is data, not destiny. Then go back to the validated biomarkers and a doctor who actually reads them.